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call-back for other reasons, to call-back/second prescrip-
tion. Regardless of the drug prescribed, the utility to the
physician of a given outcome is the same.
RESULTS: Fewer call-backs and repeat visits pursuant 
to moxiﬂoxacin resulted in the highest expected value
(0.90), compared to levoﬂoxacin (0.89) and Amoxicillin
(0.87), when the lowest utility was 0.25. A sensitivity
analysis showed consistent results, with 0.86 for Moxi-
ﬂoxacin, 0.85 for Levoﬂoxacin and 0.82 for Amoxicillin
when the lowest utility was zero. When the lowest utility
was 0.75, all drugs yielded 0.96. 
CONCLUSION: Physicians who seek to reduce events of
call-backs, repeat visits and second prescriptions may
favor certain antibiotic regimens, such as Moxiﬂoxacin,
for the treatment of acute sinusitis. This is more relevant
when physicians put a higher premium on reduced events,
that is when the spread in utilities is larger (0.25 and
1.00), than when the spread is smaller (0.75 and 1.00).
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OBJECTIVES: Appropriate use of antibiotics is a major
healthcare issue in view of increasing worldwide bacterial
resistance to antibiotics. Treatment of otitis media is the
most frequent reason for administering antibiotics to chil-
dren in the United States. This study examined physicians’
prescribing pattern(s) for otitis media in children and
compared them with therapeutic guidelines issued by the
American Academy of Pediatrics, Family Physicians, and
Otolaryngology, for appropriateness.
METHODS: Appropriateness of antibiotics was esti-
mated across patient and physician factors. Patient
factors such as age, sex, race, geographical location and
payment source were compared with physician variables
such as specialty, practice settings, geographic location
and referral status for prescribing appropriateness. Data
from the (1997) National Ambulatory Medical Care
Survey (NAMCS) were utilized. Patients of age less than
or equal to 12 years with a principal diagnosis of otitis
media were analyzed using multiple linear and binomial
logit regression models. Appropriate antibiotics were
deﬁned as those that are recommended by the guidelines.
The dosage of antibiotics was conﬁrmed by IMS Health
Inc. and the advice of a practicing otolaryngologist.
RESULTS: Pediatricians and otolaryngologists prescribed
more appropriate and less expensive antibiotics such 
as amoxicillin, ampicillin and sulfamethoxazole (R2 =
0.144). Internists and family practice physicians pre-
scribed more expensive second line antibiotics (R2 =
0.178). There was no relation between the physician’s
specialty and patient’s age for inappropriate antibiotics
prescribing (R2 = 0.345). The probability of appropriate
prescribing was higher for a physician from the northeast
and midwest than for a physician from the south (R2 =
0.167). Appropriate prescribing was not inﬂuenced by
whether the patient was referred (R2 = 0.456).
CONCLUSIONS: Physician’s specialty inﬂuences antibi-
otics prescribing for otitis media. Otolaryngologists and
pediatricians appear to prescribe appropriately, while
general practice physicians may not be prescribing the
appropriate, less expensive antibiotics.
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In the USA, macrolides are the dominant choice for initial
outpatient treatment for community-acquired pneumonia
(CAP). However, there is no consensus on second-line
therapy. Cephalosporins, quinolones, beta-lactams and
other macrolides are all commonly prescribed.
OBJECTIVE: To compare outcomes for different second-
line treatment strategies in outpatient treatment of CAP.
METHODS: We employed a previously developed and
validated probabilistic model to calculate treatment
failure rates for adult CAP with no major comorbidities.
We considered four choices for second-line therapy 
following initial treatment with the macrolide azithro-
mycin (AZI): cefuroxime (CEF), levoﬂoxacin (LEV),
amoxycillin-clavulanate (AMC) and clarithromycin
(CLA). Distribution of causative pathogens was based on
literature. We used surveillance data for the USA from the
1999–2000 PROTEKT study, and applied pharmacoki-
netic/pharmacodynamic breakpoints to determine resis-
tance levels for streptococcus pneumoniae (SP) and
haemophilus inﬂuenzae (HI). Intracellular organisms
were assumed 100% susceptible to CLA, LEV but resis-
tant to CEF, AMC. Other bacteria were assumed 50%
susceptible to all four drugs. We used published estimates
of pathogen-speciﬁc rates of spontaneous resolution. We
assumed 20% of initial treatment failures and 100% of
second-line treatment failures were hospitalized. We esti-
mated that 90% of susceptible organisms would respond
to treatment.
RESULTS: In SP, the most common cause of CAP, there
was substantial cross-resistance between AZI and the
second-line drugs, except for LEV. For example, SP was
86.6% susceptible to CEF when it was susceptible to AZI,
but only 16.3% susceptible to CEF when resistant to AZI.
The model estimated that in 59.5% of cases the initial
treatment with AZI would be successful and 5.9% would
be hospitalized following initial treatment failure. An
additional 5.2% would be hospitalized if treated with
LEV, 9.1% with AMC, 13.3% with CEF and 19.3% with
CLA. 
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CONCLUSION: Selection of appropriate second-line
therapy should be based on coverage and local cross-
resistance patterns.
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OBJECTIVES: To compare patient treatment according
to practice guidelines and the Joint Commission on the
Accreditation of Healthcare Organizations (JCAHO)
outcome measures by hospital type. To investigate
various factors associated with patient treatment accord-
ing to guidelines.
METHODS: Data from 2,238 patients with CAP were
collected from 61 hospitals during a 3-month period.
Patient data included demographic, antimicrobial selec-
tion, and outcome data. Univariate/multivariate statisti-
cal analyses were conducted.
RESULTS: Compared to teaching hospitals, a signiﬁ-
cantly higher percentage of patients admitted to commu-
nity hospitals received treatment in accordance with
treatment guidelines (84% versus 78%). Patients admit-
ted to community hospitals received treatment according
to the 1993 American Thoracic Society (ATS) guidelines
(53% versus 46%), whereas patients admitted to teach-
ing hospitals received treatment according to the Centers
for Disease Control and Prevention guidelines (CDC)
(27% versus 21%). A patient level logistic regression
analyses showed that admission to community hospitals
(odds ratio; OR = 1.9, p < 0.001), hospitals with a CAP
care plan (OR = 1.5, p < 0.01), and higher severity of
illness score (OR = 1.1, p < 0.002) were signiﬁcantly asso-
ciated with receiving care according to practice guide-
lines. However, patients admitted to the ICU (OR = 0.04,
p < 0.001) and having a neoplastic disease comorbidity
(OR = 0.45, p < 0.0002) or congestive heart failure (OR
= 0.68, p < 0.021) were signiﬁcantly less likely to receive
treatment according to guidelines. Admission to a small,
medium or large hospital had no signiﬁcant effect on
receiving treatment according to guidelines. Finally, there
was no signiﬁcant difference between hospitals in terms
of data collection for JCAHO Core Performance 
Measures.
CONCLUSIONS: Most patients with CAP are prescribed
antimicrobial drug therapy concomitant with the guide-
lines and hospitals are variably collecting data that will
help achieve the JCAHO core performance measures.
Patients admitted to community hospitals receive treat-
ment in accordance with CAP guidelines more often than
patients admitted to teaching hospitals, controlling for
other factors that impact patient treatment choice.
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OBJECTIVES: To identify the relationship of physician
reported risk factors to the incidence of hospitalizations
after the initiation of Palivizumab (Synagis TM) therapy
for ﬁrst season prophylaxis to respiratory syncytial virus
(RSV).
METHODS: Participants from Caremark’s specialty
pharmacy database who initiated Palivizumab therapy for
the 2001–02 season were analyzed on physician reported
risk factors prior to therapy initiation for one large payer.
These risk factors include, respiratory related hospital-
izations, older siblings, multiple births, exposure to
smoke, chronic illness diagnosis, medical treatment,
daycare and unspeciﬁed risk. We assessed the proportion
of risk factors within the population at the initiation of
therapy for ﬁrst season infant exposure. The relationship
between these risk factors and post-therapy initiation 
hospitalization rates will be assessed using multivariate
analysis. The study period was for participants born after
01 April 2001.
RESULTS: 410 participants (age = 156 +/- 63 days) 
who presented prescriptions for Palivizumab through
Caremark’s Specialty Pharmacy for the 2001–2002 RSV
season were analyzed. On average, infants had 1.23 +/-
1.05 risk factors. We identiﬁed 4.15% of the infants had
a reported respiratory hospitalization prior to initiation
of Palivizumab therapy. Other risk factors prior to
therapy initiation were distributed as follows: 33.9%
Older Siblings, 30.24% Multiple Births, 7.07% Exposure
to Smoke, 5.37% Chronic Illness Diagnosis, 22.2%
Medical Treatment, 10.0% Daycare Exposure, and
14.39% Unspeciﬁed Risk. Post therapy initiation hospi-
talization rates for the 2001–2002 RSV season are cur-
rently being collected and results of the multivariate
analysis will be presented.
CONCLUSION: A priori variables to direct and optimize
therapeutic management of at-risk RSV infant popula-
tions are essential. These ﬁndings on hospitalization rates
associated with physician reported risk factors would
support the decision making of both pharmacy and
provider organizations.
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